Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists

BCTX - BriaCell Therapeutics Corp. Stock Price, Fair Value and News

$12.48-0.20 (-1.58%)
Delayed as of 09 Oct 2025, 02:05 pm ET
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

BCTX Price Action

Last 7 days

0.9%

Last 30 days

58.7%

Last 90 days

-38.7%

Trailing 12 Months

17.4%

BCTX Stock Price

BCTX RSI Chart

2025FebMarAprMayJunJulAugSepOct020406080100

BCTX Valuation

Market Cap

8.6M

Price/Earnings (Trailing)

-0.44

Price/Sales (Trailing)

1.7K

Price/Free Cashflow

-0.36

BCTX Price/Sales (Trailing)

20232024202502K4K6K8K10K

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

BCTX Fundamentals

BCTX Revenue

Revenue (TTM)

3.1K

20192020202120224K6K8K10K12K14K16K

BCTX Earnings

Earnings (TTM)

-19.4M

Earnings Growth (Yr)

-457.1%

Earnings Growth (Qtr)

2.61%

2019202020212022202320242025-30M-25M-20M-15M-10M-5M0

BCTX Profitability

Return on Equity

-162.75%

Return on Assets

-114.31%

Free Cashflow Yield

-280.19%

BCTX Investor Care

Shares Dilution (1Y)

248.16%

Diluted EPS (TTM)

-16.75

Revenue Breakdown

As of: Apr 30, 2022
FebMarApr15K20K25K30K35K
Total
TotalValuePercent

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Oct2019AprJulOct2020AprJulOct2021AprJul4K6K8K10K12K14K16K
Net sales
YearQ1Q2Q3Q4
20220000
2021003.1K0
20200000
20190012.0K0
20180016.0K0
Get all data in R, Python etc through our Historical Stock Data APIs

About BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp., an immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab. The company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test that determines the patients' HLA types. It has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates; and a cooperative research and development agreement with the National Cancer Institute to conduct preclinical studies to develop and test Bria-OTS cellular immunotherapy as a treatment for cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.
0
 CEO
 WEBSITEbriacell.com
 SECTORHealthcare
 INDUSTRYBiotechnology

BriaCell Therapeutics Corp. Frequently Asked Questions

What is the ticker symbol for BriaCell Therapeutics Corp.? What does BCTX stand for in stocks?

BCTX is the stock ticker symbol of BriaCell Therapeutics Corp.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of BriaCell Therapeutics Corp. (BCTX)?

As of Wed Oct 08 2025, market cap of BriaCell Therapeutics Corp. is 8.59 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BCTX stock?

You can check BCTX's fair value in chart for subscribers.

Is BriaCell Therapeutics Corp. a good stock to buy?

The fair value guage provides a quick view whether BCTX is over valued or under valued. Whether BriaCell Therapeutics Corp. is cheap or expensive depends on the assumptions which impact BriaCell Therapeutics Corp.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BCTX.

What is BriaCell Therapeutics Corp.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Oct 08 2025, BCTX's PE ratio (Price to Earnings) is -0.44 and Price to Sales (PS) ratio is 1.67 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BCTX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on BriaCell Therapeutics Corp.'s stock?

In the past 10 years, BriaCell Therapeutics Corp. has provided -0.326 (multiply by 100 for percentage) rate of return.